SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is attracting significant market attention as traders bet on a potential short squeeze amid high short interest and heavy institutional buying. The community remains focused on upcoming regulatory catalysts, global manufacturing expansion for its cell therapy platform, and the company's long-term potential to transform oncology treatment.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is experiencing significant volatility as investors weigh a strong growth narrative against persistent stock price pressure near annual lows, fueled by concerns over Alani Nu integration and competitive dynamics. The community is actively debating whether current levels represent an institutional accumulation phase ahead of upcoming earnings or reflect deeper structural headwinds in the energy drink sector.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending following the successful closure of a $600 million AAA-rated asset-backed securities transaction, which has bolstered investor confidence in its AI-driven credit underwriting model. The community is currently focused on the stock's potential for a recovery, emphasizing its move toward sustained profitability and the expansion of its institutional partner network despite broader macro-economic and geopolitical headwinds.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is drawing heavy investor attention as the company aggressively pivots to value-focused menus, including new low-cost offerings and specialty drink expansions designed to combat rising operational costs and intense competition. Community sentiment is mixed, with some traders betting on a defensive rotation into the stock as a recession hedge, while others voice concerns regarding menu quality and the effectiveness of current leadership.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing significant volatility driven by ongoing debates over Elevidys clinical efficacy and concerns regarding Roche's decision to initiate a new global Phase 3 trial for the therapy. While the community remains deeply polarizedwith some investors highlighting undervaluation relative to the company's approved portfolio and others raising alarms over regulatory hurdles and potential cash burnsentiment is further pressured by aggressive analyst downgrades and persistent short interest.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending as investors weigh strong underlying enterprise growth and AI-driven demand against significant short-term volatility and sector-wide sentiment shifts. The community remains divided, with many traders debating whether recent pullbacks represent an attractive entry point for a long-term AI infrastructure play or a deeper valuation reset for the software sector.

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Ernexa Therapeutics is seeing heightened market activity driven by positive preclinical data for its ERNA-101 ovarian cancer therapy, which showed complete tumor elimination in syngeneic models. While some members of the community are optimistic about the company's valuation relative to its pipeline and MD Anderson collaboration, others remain skeptical, pointing to the company's history of reverse splits and the inherent risks of early-stage, pre-human clinical research.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is experiencing massive volume and price volatility driven by a new hedge fund report positioning the company as a key stealth supplier of optical components for AI data centers and smart glasses. The community is actively debating whether this movement signals a long-term fundamental rerating or if it represents a volatile 'buy-the-news' trap prone to rapid reversals.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is drawing intense investor attention as community members debate whether the stock is undergoing a genuine AI infrastructure re-rating or experiencing an overextended speculative bubble following strong earnings. Discussion is currently focused on the company's ambitious AGI CPU demand and the tension between its long-term growth potential and immediate concerns over supply constraints and valuation.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is currently trending due to a massive disconnect between its strong fundamentals and recent stock price volatility, with investors debating whether the stock is a 'profit machine' or vulnerable to dilution from a shelf offering. The community is sharply divided, with bulls pointing to record-breaking margins and AI-driven growth, while some bears are signaling caution regarding potential SEC investigation risks and the broader software sector's recent underperformance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Needham raised its 2026 e-commerce revenue forecast from $1.05 billion to $1.45 billion.</li><li>The firm noted that AppLovin’s share price has recently retreated from its peak a month ago, presenting a potential buying opportunity for investors.</li><li>Needham also highlighted the potential for upside beyond current projections, suggesting that AppLovin could follow a growth trajectory similar to TikTok's.</li></ul>AppLovin (APP) has received a bullish upgrade from Needham, which raised its rating to ‘Buy’ from ‘Hold’ and set a $700 price target, reflecting renewed confidence in the company’s e-commerce growth potential for 2026.&nbsp;The price target implies a potential 33% upside from the company’s Friday closing price.&nbsp;<h2 class="st-heading-2">Revenue Growth Outlook</h2>The move comes after Needham observed strong performance in AppLovin’s e-commerce segment, particularly driven by its self-service advertising platform. The firm raised its 2026 e-commerce revenue forecast from $1.05 billion to $1.45 billion, citing increased advertiser adoption and higher spending that could offset the usual seasonal dip in the first quarter.&nbsp;<a href="https://stocktwits.com/symbol/APP">AppLovin stock</a> traded over 5% higher on Monday morning. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory while message volume changed to ‘high’ from ‘extremely high’ levels in 24 hours.&nbsp;The firm noted that AppLovin’s share price has recently retreated from its peak a month ago, presenting a potential buying opportunity for investors. Needham also highlighted the potential for upside beyond current projections, suggesting that AppLovin could follow a growth trajectory similar to TikTok in the e-commerce and digital advertising spaces.<h2 class="st-heading-2">Fourth-Quarter Earnings&nbsp;</h2>The company is scheduled to report its fourth-quarter earnings on February 11 and expects revenue in the range of $1.57 billion and $1.6 billion. Analysts see a revenue of $1.61 billion and earnings per share of $2.95.&nbsp;Founded in 2012, AppLovin specializes in mobile advertising technology and software solutions for app developers. Its platform connects advertisers with consumers through programmatic campaigns while enabling app publishers to monetize effectively.&nbsp;However, last week, Capitalwatch released a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.capitalwatch.com/">report</a> accusing AppLovin’s main shareholders, Hao Tang and Ling Tang, of using the company to move large amounts of illegal money. The report claimed that criminal groups paid AppLovin huge advertising fees through its AXON and Array systems to launder illicit funds.&nbsp;APP stock has gained over 58% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/inmd-stock-jumped-today-what-is-powering-the-rally/cmy7tBNR4h4">INMD Stock Jumped Nearly 13% Today – What’s Powering The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the AppLovin Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

AppLovin Stock Gets A Needham Upgrade – Why Does The Firm See A 33% Upside Potential For The Stock?

Needham said it observed strong performance in AppLovin’s e-commerce segment, particularly driven by its self-service advertising platform.

Equity

Needham said it observed strong performance in AppLovin’s e-commerce segment, particularly driven by its self-service advertising platform.


<ul class="summary-bullets"><li>It is now unclear when the company would apply for approval of the gene therapy, it said.</li><li>uniQure, however, added that it intends to communicate with the FDA to determine a path forward toward approval of the therapy.&nbsp;</li><li>uniQure CEO termed the meeting outcome “unexpected.” &nbsp;</li></ul>uniQure N.V. (QURE) no longer believes that the U.S. Food and Drug Administration considers data from an early-to mid-stage trial of its investigational gene therapy for Huntington’s disease sufficient for approval, the company said on Monday.The company recently met with the agency, and although the minutes of the meeting have not been received, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/03/3179114/0/en/uniQure-Provides-Regulatory-Update-on-AMT-130-for-Huntington-s-Disease.html">believes</a> that the FDA no longer considers the data from the AMT-130 trial adequate to provide primary evidence in support of an application for approval.As a result, it is now unclear when the company would apply for approval of the gene therapy, it said. uniQure, however, added that it intends to communicate with the FDA to determine a path forward toward approval of the therapy.<h2 class="st-heading-2">CEO Reacts</h2>uniQure CEO termed the meeting outcome “unexpected.”“We are surprised by the FDA’s feedback at the recent pre-BLA meeting, which is a drastic change from the guidance the FDA provided in November 2024 that data from the ongoing Phase I/II studies, compared to a natural history external control, may serve as the primary basis for a BLA submission under the Accelerated Approval pathway,” CEO Matt Kapusta said.The company also stated that it intends to engage in further communications with other regulatory agencies while working with the FDA.<h2 class="st-heading-2">Expert Take</h2>Stifel analyst Annabel Samimy said that the news regarding the FDA's reversal on the approvability of uniQure's AMT-130 based on early to mid-stage trial data on the surface injects another layer of uncertainty into the workings of the FDA and their receptivity to gene therapy, more specifically.The analyst, however, does not expect this to impact Regenxbio’s (RGNX) rare disease programs. Meanwhile, Raymond James added that it does not expect the meeting outcome to impact Biohaven (BHVN) either.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>QURE stock traded 55% lower at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/QURE">QURE stock</a> fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.QURE stock is up 72% this year and approximately 445% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tg-therapeutics-stock-soars-after-company-ups-guidance-for-multiple-sclerosis-drug/cL2NEPSR3zl">TG Therapeutics Stock Soars After Company Ups Guidance For Multiple Sclerosis Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the uniQure logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

uniQure Stock Tumbled 55% Today: What’s The FDA Angle?

The company recently met with the FDA and believes that the agency no longer considers the data from an early-to-mid-stage trial of its investigational gene therapy sufficient for approval.

Alger ETF Trust (The) - Alger Mid Cap 40 ETF

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

Current Price	$22.52
Prev Close	$21.79
Open	$22.23
Dividend Yield	N/A
50-Day Moving Average	$20.33
Beta	N/A
Avg. Volume	29,685.97
PE Ratio	N/A

52-Week High	$23.36
52-Week Low	$16.56
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

FRTY
Alger Funds - Alger Mid Cap 40 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest FRTY News

FRTYAlger Funds - Alger Mid Cap 40 ETF